LON:MPH - Mereo BioPharma Group Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
GBX 196 0.00 (0.00 %)
(As of 12/10/2018 02:24 AM ET)
Previous CloseGBX 196
Today's RangeGBX 196 - GBX 196
52-Week RangeGBX 290 - GBX 339.99
VolumeN/A
Average Volume266 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Mereo BioPharma Group plc, a specialty biopharmaceutical company, acquires, develops, and commercializes therapeutics for the treatment of rare and specialty diseases. Its product candidates include BPS-804, a monoclonal antibody, which is in Phase IIb clinical trial for the treatment of osteogenesis imperfecta; AZD-9668, an oral small molecule that has been completed Phase I clinical trial to treat Alpha-1 antitrypsin deficiency; BGS-649, an oral aromatase inhibitor, which is in Phase IIb clinical trial for the treatment of hypogonadal hypogonadism; and BCT-197, an oral p38 MAP kinase inhibitor that is in Phase II clinical trial to treat acute exacerbations of chronic obstructive pulmonary disease. Mereo BioPharma Group plc was founded in 2015 and is headquartered in London, the United Kingdom.

Receive MPH News and Ratings via Email

Sign-up to receive the latest news and ratings for MPH and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange LON
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolLON:MPH
Previous Symbol
CUSIPN/A
PhoneN/A

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

EmployeesN/A
Outstanding SharesN/A
Market Cap£0.00
OptionableNot Optionable

Mereo BioPharma Group (LON:MPH) Frequently Asked Questions

What is Mereo BioPharma Group's stock symbol?

Mereo BioPharma Group trades on the London Stock Exchange (LON) under the ticker symbol "MPH."

Has Mereo BioPharma Group been receiving favorable news coverage?

News stories about MPH stock have trended somewhat positive recently, InfoTrie Sentiment reports. The research firm scores the sentiment of media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Mereo BioPharma Group earned a media sentiment score of 0.8 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 1.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the near term.

Who are some of Mereo BioPharma Group's key competitors?

Who are Mereo BioPharma Group's key executives?

Mereo BioPharma Group's management team includes the folowing people:
  • Dr. Denise Scots-Knight, Co-Founder, Chief Exec. Officer & Exec. Director (Age 59)
  • Mr. Richard Crispin Morgan Jones, CFO & Exec. Director (Age 52)
  • Mr. Charles Sermon, Co-Founder, Gen. Counsel & Company Sec. (Age 49)
  • Dr. Alastair MacKinnon M.D., Co-Founder & Chief Medical Officer (Age 48)
  • Mr. John Richard, Co-Founder & Head of Corp. Devel. (Age 61)

How do I buy shares of Mereo BioPharma Group?

Shares of MPH and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Mereo BioPharma Group's stock price today?

One share of MPH stock can currently be purchased for approximately GBX 196.

What is Mereo BioPharma Group's official website?

The official website for Mereo BioPharma Group is http://mereobiopharma.com/.


MarketBeat Community Rating for Mereo BioPharma Group (LON MPH)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  91 (Vote Outperform)
Underperform Votes:  65 (Vote Underperform)
Total Votes:  156
MarketBeat's community ratings are surveys of what our community members think about Mereo BioPharma Group and other stocks. Vote "Outperform" if you believe MPH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MPH will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/10/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel